No Data
Why We're Not Concerned Yet About PharmaResources (Shanghai) Co., Ltd.'s (SZSE:301230) 30% Share Price Plunge
Brokerage morning meeting highlights: The USA has increased tariffs on China, but the impact on these industries in the A-shares may be limited.
In today's brokerage morning meeting, GF SEC believes that the USA's tariffs on China have a limited impact on the A-share Computer Industry; China Securities Co.,Ltd. suggested being Bullish on the Innovative Drugs industry that is currently not affected by tariffs; Galaxy Securities stated that Deep Sea Technology has entered a new stage in Global Strategy, focusing on opportunities in core equipment.
Does PharmaResources (Shanghai) (SZSE:301230) Have A Healthy Balance Sheet?
GTJA: Continuous iteration of anti-tumor therapies, domestic new drugs welcome breakthroughs.
GTJA focuses on products with significant differentiation advantages and leading companies in innovative segments.
Hongbo Pharmaceutical (301230.SZ): plans to participate in the establishment of the partnership Lichen Yanhe.
On March 10, Gelonghui reported that Hongbo Biomedical (301230.SZ) announced that to meet the company's Global Strategy needs, it has signed a partnership agreement with Shanghai Liyuan Enterprise Management Partnership (Limited Partnership) and Shanghai Licheng Yuanding Private Investment Fund Partnership (Limited Partnership) to jointly establish the Shanghai Licheng Yanhe Enterprise Management Partnership (Limited Partnership) (referred to as "Licheng Yanhe"). The company contributes 7.3 million yuan in its own funds, accounting for 28.08% of the contribution ratio. This external investment focuses on early investment in Biomedical.
CSC: The potential of AI in pharmaceuticals is being released and is expected to reshape the future landscape of medicine.
AI is expected to reshape the model of drug discovery and bring subtle yet continuous cost reduction and efficiency improvement to the pharmaceutical Industry, driving the rapid growth of AI pharmaceutical pipelines and markets, and being Bullish on the long-term development potential and prospects of the AI pharmaceutical Industry.
Declining Stock and Decent Financials: Is The Market Wrong About PharmaResources (Shanghai) Co., Ltd. (SZSE:301230)?
